Primary Tumour Resection Could Improve the Survival of Unresectable Metastatic Colorectal Cancer Patients Receiving Bevacizumab-Containing Chemotherapy

Cellular Physiology and Biochemistry

Volumn 39, Issue 3, 2016, Pages 1239-1246

  Wang, Zhiming ^a   Liang, Li ^a   Yu, Yiyi ^a   Wang, Yan ^a   Zhuang, Rongyuan ^a   Chen, Yong ^a   Cui, Yuehong ^a   Zhou, Yuhong ^a   Liu, Tianshu ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Bevacizumab; Chemotherapy; Metastatic colorectal cancer; Primary tumour resection (PTR)

Indexed keywords

BEVACIZUMAB; CAPECITABINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DEOXYCYTIDINE; PLATINUM COMPLEX;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; CONTINUOUS INFUSION; DRUG FATALITY; EMERGENCY SURGERY; FEMALE; HUMAN; INCIDENCE; INTESTINE OBSTRUCTION; INTESTINE PERFORATION; MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CANCER; MULTIPLE CYCLE TREATMENT; OBSERVATIONAL STUDY; OVERALL SURVIVAL; PRIMARY TUMOR; PRIMARY TUMOR RESECTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; QUALITY OF LIFE; STENT; SYSTEMIC THERAPY; THERAPY EFFECT; TREATMENT OUTCOME; TUMOR BLEEDING; ANALOGS AND DERIVATIVES; CASE CONTROL STUDY; COLORECTAL NEOPLASMS; DISEASE COURSE; GAMMA RADIATION; LYMPH NODE METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; SURVIVAL ANALYSIS; THERAPEUTIC USE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BEVACIZUMAB; CAMPTOTHECIN; CASE-CONTROL STUDIES; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; DISEASE PROGRESSION; FEMALE; FLUOROURACIL; GAMMA RAYS; HUMANS; LEUCOVORIN; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; PROSPECTIVE STUDIES; QUALITY OF LIFE; STENTS; SURVIVAL ANALYSIS;

EID: 84986893153     PISSN: 10158987     EISSN: 14219778     Source Type: Journal    
DOI: 10.1159/000447829     Document Type: Article

References (30)

1. Cook AD, Single R, McCahill LE: Surgical resection of primary tumors in patients who present with stage IV colorectal cancer: An analysis of surveillance, epidemiology, and end results data, 1988 to 2000. Ann Surg Oncol 2005;12:637-645.
2. Edge S, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A: AJCC Cancer Staging Handbook -From the AJCC Cancer Staging Manual, ed 7. Springer-Verlag New York, 2010.
3. Compton CC, Greene FL: The staging of colorectal cancer: 2004 and beyond. CA Cancer J Clin 2004; 54: 295-308.
4. Kopetz S, Chang GJ, Overman MJ, Eng C, Sargent DJ, Larson DW, Grothey A, Vauthey JN, Nagorney DM, McWilliams RR: J Clin Oncol 2009;27:3677-3683.
5. Hurwitz H1, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350: 2335-2342.
6. Kabbinavar FF, Hambleton J, Mass RD, Hurwitz HI, Bergsland E, Sarkar S: Combined analysis of efficacy: the addition of Bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 2005;23:3706-3712
7. Saltz LB, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, Couture F, Sirzén F, Cassidy J: Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008;26:2013-2019.
8. Petrelli F, Borgonovo K, Cabiddu M, Ghilardi M, Lonati V, Maspero F, Sauta MG, Beretta GD, Barni S: FOLFIRI-Bevacizumab as first-line chemotherapy in 3500 patients with advanced colorectal cancer: a pooled analysis of 29 published trials. Clin Colorectal Cancer 2013;12:145-151.
9. McCahill LE, Yothers G, Sharif S, Petrelli NJ, Lai LL, Bechar N, Giguere JK, Dakhil SR, Fehrenbacher L, Lopa SH, Wagman LD, O'Connell MJ, Wolmark N: Primary mFOLFOX6 Plus Bevacizumab Without Resection of the Primary Tumor for Patients Presenting With Surgically Unresectable Metastatic Colon Cancer and an Intact Asymptomatic Colon Cancer: Definitive Analysis of NSABP Trial C-10. J Clin Oncol 2012;30:3223-3228.
10. Mäkelä J, Haukipuro K, Laitinen S, Kairaluoma MI: Palliative operations for colorectal cancer. Dis Colon Rectum 1990;33:846-850.
11. Venderbosch S, de Wilt JH, Teerenstra S, Loosveld OJ, van Bochove A, Sinnige HA, Creemers GJ, Tesselaar ME, Mol L, Punt CJ, Koopman M: Ann Surg Oncol 2011;18:3252-3260.
12. Karoui M, Roudot-Thoraval F, Mesli F, Mitry E, Aparicio T, Des Guetz G, Louvet C, Landi B, Tiret E, Sobhani I: Primary colectomy in patients with stage IV colon cancer and unresectable distant metastases improves overall survival: results of a multicentric study. Dis Colon Rectum 2011;54:930-938.
13. Poultsides GA, Servais EL, Saltz LB, Patil S, Kemeny NE, Guillem JG, Weiser M, Temple LK, Wong WD, Paty PB: Outcome of primary tumor in patients with synchronous stage IV colorectal cancer receiving combination chemotherapy without surgery as initial treatment. J Clin Oncol 2009;27: 3379-3384.
14. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216.
15. Faron M, Pignon JP, Malka D, Bourredjem A, Douillard JY, Adenis A, Elias D, Bouché O, Ducreux M: Is primary tumour resection associated with survival improvement in patients with colorectal cancer and unresectable synchronous metastases? A pooled analysis of individual data from four randomised trials. Eur J Cancer 2015;51:166-176.
16. Anwar S, Peter MB, Dent J, Scott NA: Palliative excisional surgery for primary colorectal cancer in patients with incurable metastatic disease. Is there a survival benefit? A systematic review. Colorectal Dis 2012;14:920-930.
17. Ahmed S, Leis A, Fields A, Chandra-Kanthan S, Haider K, Alvi R, Reeder B, Pahwa P: Survival impact of surgical resection of primary tumor in patients with stage IV colorectal cancer: Results from a large population-based cohort study. Cancer 2014;120:683-691.
18. Kim MS, Chung M, Ahn JB, Kim CW, Cho MS, Shin SJ, Baek SJ, Hur H, Min BS, Baik SH, Kim NK: Clinical significance of primary tumor resection in colorectal cancer patients with synchronous unresectable metastasis. J Surg Oncol 2014;110:214-221.
19. Ghiringhelli F, Bichard D, Limat S, Lorgis V, Vincent J, Borg C, Berthou J, Orry D, Ortega-Deballon P, Lakkis Z, Facy O, Heyd B, Rat P, Nerich V, Ladoire S: Bevacizumab efficacy in metastatic colorectal cancer is dependent on primary tumor resection. Ann Surg Oncol 2014;21:1632-1640.
20. Cirocchi R, Trastulli S, Abraha I, Vettoretto N, Boselli C, Montedori A, Parisi A, Noya G, Platell C: Non-resection versus resection for an asymptomatic primary tumour in patients with unresectable stage IV colorectal cancer. Cochrane Database Syst Rev DOI: 10.1002/14651858.
21. McCahill LE, Yothers G, Sharif S, Petrelli NJ, Lai LL, Bechar N, Giguere JK, Dakhil SR, Fehrenbacher L, Lopa SH, Wagman LD, O'Connell MJ, Wolmark N: Primary mFOLFOX6 plus bevacizumab without resection of the primary tumor for patients presenting with surgically unresectable metastatic colon cancer and an intact asymptomatic colon cancer: definitive analysis of NSABP trial C-10. J Clin Oncol 2012; 30: 3223-3228.
22. Ahmed S, Shahid RK, Leis A, Haider K, Kanthan S, Reeder B, Pahwa P: Should noncurative resection of the primary tumour be performed in patients with stage iv colorectal cancer? A systematic review and meta-analysis. Curr Oncol 2013;20:e420-e441.
23. Nitzkorski JR, Farma JM, Watson JC, Siripurapu V, Zhu F, Matteotti RS, Sigurdson ER: Outcome and natural history of patients with stage IV colorectal cancer receiving chemotherapy without primary tumor resection. Ann Surg Oncol 2012;19:379-383.
24. Seo GJ, Park JW, Yoo SB, Kim SY, Choi HS, Chang HJ, Shin A, Jeong SY, Kim DY, Oh JH: Intestinal complications after palliative treatment for asymptomatic patients with unresectable stage IV colorectal cancer. J Surg Oncol 2010;102:94-99.
25. Tebbutt NC, Norman AR, Cunningham D, Hill ME, Tait D, Oates J, Livingston S, Andreyev J: Intestinal complications after chemotherapy for patients with unresected primary colorectal cancer and synchronous metastases. Gut 2003;52:568-573.
26. Zhang W, Zou C, Pan L, Xu Y, Qi W, Ma G, Hou Y, Jiang P: MicroRNA-140-5p inhibits the progression of colorectal cancer by targeting VEGFA. Cell Physiol Biochem 2015;37:1123-1133.
27. National Comprehensive Cancer Network. NCCN Clinical PracticeGuidelines in Oncology: Colon V3.2015.
28. Heinemann V, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Lerchenmüller C, Kahl C, Seipelt G, Kullmann F, Stauch M, Scheithauer W, Hielscher J, Scholz M, Müller S, Link H, Niederle N, Rost A, Höffkes HG, Moehler M, Lindig RU, Modest DP, Rossius L, Kirchner T, Jung A, Stintzing S: FOLFIRI plus cetuximab versus FOLFIRI plus Bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol 2014; 15: 1065-1075.
29. Venook AP, Niedzwiecki D, Lenz HJ, Innocenti F, Mahoney MR, O'Neil BH, Shaw JE, Polite BN, Hochster HS, Atkins JN, Goldberg RM, Mayer RJ, Schilsky RL, Bertagnolli MM, Blanke CD: CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with K-RAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum. J Clin Oncol 2014;32:5s
30. Turner N, Tran B, Tran PV, Sinnathamby M, Wong HL, Jones I, Croxford M, Desai J, Tie J, Field KM, Kosmider S, Bae S, Gibbs P: Primary tumor resection in patients with metastatic colorectal cancer is associated with reversal of systemic inflammation and improved survival. Clin Colorectal Cancer 2015;14:185-191.